Trial reportArchives of dermatological research2025
The efficacy of topical cetirizine using microneedling in androgenetic alopecia male patients.
Trial report in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hair follicle regeneration technology: from microenvironment regulation to functional reconstruction.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAndrogenetic alopecia (AGA) affects both sexes equally and lasts long. AGA is the most common kind of hair loss in men. Gradual, pattern-based hair thinning on the scalp is a hallmark of the disease. The front, back, center, and sides of a man's head are the most common areas where hair thinning and loss occur.
aimTo evaluate the efficacy of microneedling-administered topical cetirizine in treating androgenetic alopecia in men.
methodsA total of 80 AGA male patients were randomly assigned to this single-blind, parallel placebo-controlled study conducted at Beni-Suef University Hospital's Dermatology Outpatient Clinic. Researchers allocated 40 patients to undergo topical cetirizine microneedling (MN) and 40 patients to saline MN for 8 weeks.
resultsIn the 8th week, the cetirizine group demonstrated a greater prevalence of vellus hair (70.0%) than the saline group (30.0%), with a statistically significant difference (p-value = 0.001). The majority of patients administered cetirizine by MN exhibited enhanced hair density (80.0%) in contrast to 25.0% in the saline group, with a statistically significant difference between the two groups (p-value = 0.001). No notable adverse effects linked to the administration of cetirizine by MN were reported.
conclusionThe microneedling of 1% topical cetirizine proved efficient in promoting hair growth without problems in the treatment of male androgenetic alopecia.
Indexed as
Identifiers
40167621What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.